496 related articles for article (PubMed ID: 17320999)
21. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
22. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
Weir MR
J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
[TBL] [Abstract][Full Text] [Related]
23. Prospects for angiotensin receptor blockers in diabetic retinopathy.
Sjølie AK
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
[TBL] [Abstract][Full Text] [Related]
24. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
25. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
Weir MR
Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
Giles TD
Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
[TBL] [Abstract][Full Text] [Related]
27. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
Cooper ME; Tikellis C; Thomas MC
J Hypertens Suppl; 2006 Mar; 24(1):S57-63. PubMed ID: 16601575
[TBL] [Abstract][Full Text] [Related]
28. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
Böhm M
Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
[TBL] [Abstract][Full Text] [Related]
30. RAS inhibition in hypertension.
Ibrahim MM
J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
[TBL] [Abstract][Full Text] [Related]
31. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
32. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
33. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
Mancia G
Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber MA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
[TBL] [Abstract][Full Text] [Related]
35. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
36. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
37. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
38. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
39. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]